Fibroheal Woundcare Private Limited, a pioneer in silk biomaterial-based advanced wound care solutions and medtech, has raised Rs. 14 crore in fresh capital to accelerate growth, strengthen its market leadership, and expand into developed international markets.

The funding round saw participation from existing investors, including Dr. Naresh Bhat, one of India's leading gastrointestinal and endoscopic specialists; Joseph Thomas, Co-Head, First Families, at 360 ONE Asset Management; Bharat Tandon, a silk industry veteran and former founder of Vetcare; along with Vikas K. S. and Vivek Mishra, CEO of Fibroheal.

Earlier in 2025, Fibroheal provided a successful secondary exit to early investor Telama Investment, delivering a 29.6% internal rate of return (IRR). Backed by investors including KITVEN Funds, C-CAMP, BIRAC, the Department of Biotechnology, Central Silk Board, the Ministry of Textiles, and the Government of Karnataka, the company has built a strong innovation ecosystem with nine granted patents and over 30 academic collaborations.

Fibroheal reported 77% year-on-year revenue growth in the first quarter of FY2026-27. Its products are now used in more than 500 hospitals across India, with over 150,000 patients treated using its silk protein-based wound care technologies.

The company has also partnered with US-based SYLKE to advance silk protein applications in post-operative care. An ongoing study at Johns Hopkins University, Baltimore, is evaluating silk protein-based solutions for donor site wound management.

The fresh investment will be used to strengthen commercial capabilities, scale operations, expand globally, enhance regulatory readiness, and accelerate the development of new biomaterial-based technologies.

Dr. Naresh Bhat said, "I doubled down my investment in Fibroheal seeing great potential in this company considering first move advantage around silk proteins-based care in medical field and I have seen outcomes of many patient wounds healing quickly with Fibroheal silk based technology especially D Fibroheal Ag Powder and their bandages."

Joseph Thomas said, "I have backed company previously also and have seen the growth of company and firmly believes that Fibroheal is reaching the stage for exponential growth and I am glad to be one among those who are giving wings to the future ambitions of Fibroheal."

Bharat Tandon, who co-founded Fibroheal with Vivek Mishra, said, "Fibroheal has done a tremendous job, and I wish this team all the best to do well and multiply the economic multiplier potential of Silk proteins in medtech and biotechnology arena. I am backing Fibroheal’s vision, clinical impact and demonstrated commercial trajectory."

Vivek Mishra, CEO of Fibroheal, said, "This funding positions us to strengthen our global footprint while advancing various biomaterials-based breakthrough technologies that addresses significant clinical needs. This backing is a massive validation of the amazing work our team is doing at Fibroheal and will help us in scaling our operations, regulatory readiness for global markets and go to market capabilities."